Mechanisms of LDL oxidation

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1875-1882

  Yoshida, Hiroshi ^a,b   Kisugi, Reiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI University Graduate School of Medicine   (Japan)

Author keywords

Atherosclerosis; Endothelial cell; Glycation; LDL; Lipoxygenase; Macrophage; Myeloperoxidase; Nitric oxide; Oxidation; Transition metal

Indexed keywords

FREE RADICAL; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; METAL ION; MYELOPEROXIDASE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ENDOTHELIUM CELL; ENZYME METABOLISM; HUMAN; LIPID PEROXIDATION; MACROPHAGE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

ANIMALS; HUMANS; LIPOPROTEINS, LDL; LIPOXYGENASE; METALS; NITRIC OXIDE; OXIDATION-REDUCTION; PEROXIDASE;

EID: 77957750758     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.038     Document Type: Review

References (132)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
2. Steinberg D., Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997, 95:1062-1071.
3. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
4. Fraley A.E., Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006, 17:502-509.
5. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 2008, 101:34D-42D.
6. Parthasarathy S., Litvinov D., Selvarajan K., Garelnabi M. Lipid peroxidation and decomposition-conflicting roles in plaque vulnerability and stability. Biochim Biophys Acta 2008, 1781:221-231.
7. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009, S376-S381. April Supple.
8. Baigent C., Keech A., Kearney P.M., et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
9. Nakamura H., Arakawa K., Itakura H., et al. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 369:1155-1163.
10. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8:1211-1217.
11. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
12. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343(6257):425-430.
13. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131.
14. Yoshida H., Quehenberger O., Kondratenko N., Green S., Steinberg D. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 1998, 18:794-802.
15. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240.
16. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allerg Immunol 2009, 37:4-11.
17. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
18. Parthasarathy S., Wieland E., Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989, 86:1046-1050.
19. Benz D.J., Mol M., Ezaki M., et al. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblasts expressing high levels of human 15-lipoxygenase. J Biol Chem 1995, 270:5191-5197.
20. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
21. Yoshida H., Ishikawa T., Hosoai H., et al. Inhibitory effect of tea flavonoids on the ability of cells to oxidize low density lipoprotein. Biochem Pharmacol 1999, 58:1695-1703.
22. Yoshida H., Sasaki K., Namiki Y., Sato N., Tada N. Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis 2005, 179:97-102.
23. Stocker R., Keaney J.F. New insights on oxidative stress in the artery wall. J Thromb Haemost 2005, 3:1825-1834.
24. Lee H., Shi W., Tontonoz P., et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000, 87:516-521.
25. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell 2001, 104:503-516.
26. Boullier A., Li Y., Quehenberger O., et al. Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages. Arterioscler Thromb Vasc Biol 2006, 26:1169-1176.
27. Witztum J.L., Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 2001, 11:93-102.
28. Gautier E.L., Huby T., Witztum J.L., et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009, 119:1795-1804.
29. Meagher E.A., Fitzgerald G.A. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000, 28:1745-1750.
30. Noguchi N. Novel insights into the molecular mechanisms of the antiatherosclerotic properties of antioxidants: the alternatives to radical scavenging. Free Radic Biol Med 2002, 33:1480-1489.
31. Gniwatta C., Morrow J.D., Roberts L.J., Kuhn H. Prostaglandin F2-like compounds, F2-isoplastane, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997, 17:3236-3241.
32. Berliner J.A., Subbanagounder G., Leitinger N., Watson A.D., Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001, 11:142-147.
33. Witz G. Biological interaction of a, b-unsaturated aldehydes. Free Radic Biol Med 1989, 7:333-349.
34. Girotti A.W. Lipid peroxide generation, turnover, and effector action in biological systems. J Lipid Res 1998, 39:1529-1542.
35. Karten B., Boechzelt H., Abuja P.M., Mittelbach M., Sattler W. Macrophage-enhanced formation of cholesteryl ester-core aldehydes during oxidation of low density lipoprotein. J Lipid Res 1999, 40:1240-1253.
36. Heinecke J.W., Rosen H., Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984, 74:1890-1894.
37. Steinbrecher U.P., Parthsarathy S., Leake D.S., Witztum J.L., Steinberg D. Modifications of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984, 81:3883-3887.
38. Lamb D.J., Leake D.S. The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis 1992, 94:35-42.
39. Parthasarathy S., Steinberg D. Cell-induced oxidation of LDL. Curr Opin Lipidol 1992, 3:313-317.
40. Morgan J., Leake D.S. Oxidation of low density lipoprotein by iron or copper at acidic pH. J Lipid Res 1995, 36:2504-2512.
41. Heinecke J.W. Mechanisms of oxidative damages of low density lipoprotein in human atherosclerosis. Curr Opin Lipidol 1997, 8:268-274.
42. Esterbauer H., Striegl G., Publ H., Rothender M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989, 6:67-75.
43. Stadler N., Lindner R.A., Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaque: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004, 24:949-954.
44. Gaut J.P., Heinecke J.W. Mechanisms for oxidizing low-density lipoprotein: Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med 2001, 11:103-112.
45. Ascherio A., Willet W.C. Are body iron stores related to theh risk of coronary heart disease?. N Engl J Med 1994, 330:1152-1154.
46. Miller M., Hutchins G.M. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994, 272:231-233.
47. Levy A.P. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacol Ther 2006, 112:501-512.
48. Milman U., Blum S., Shapira C., et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008, 28:341-347.
49. Levy A.P., Levy J.E., Kalet-Litman S., et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007, 27:134-140.
50. Kalet-Litman S., Moreno P.R., Levy A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 2010, 209:28-31.
51. Sparrow C.P., Olszewski J. Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions. J Lipid Res 1993, 34:1219-1228.
52. Parthasarathy S. Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl-LDL receptor. Biochim Biophys Acta 1987, 917:337-340.
53. Chait A., Heinecke J.W. Lipoprotein modification: cellular mechanisms. Curr Opin Lipidol 1994, 5:365-370.
54. Schöneich C., Dillinger U., von Bruchhausen F., Asmus K.D. Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals: reaction kinetics, and influence of oxygen and structure of thiyl radicals. Arch Biochem Biophys 1992, 292:456-467.
55. Halliwell B. Mechanisms of low-density lipoprotein oxidation. Curr Opin Lipidol 1993, 4:382-384.
56. Pfanzagl B., Tribl F., Koller E., Möslinger T. Homocysteine strongly enhances metal-catalyzed LDL oxidation in the presence of cystine and cysteine. Atherosclerosis 2003, 168:39-48.
57. Hajjar D.P., Farber L.C., Smith S.C. Oxygen tension within the arterial wall: relationships to bioenergetic metabolism and lipid accumulation. Arch Biochem Biophys 1988, 262:375-380.
58. Leake D.S. Does an acidic pH explain why low density lipoprotein is oxidized in atherosclerotic lesions?. Atherosclerosis 1997, 129:149-157.
59. Tapper H., Sundler R. Cytosolic pH regulation in mouse macrophages. Proton extrusion by plasma membrane located H+-ATPase. Biochem J 1992, 281:245-250.
60. Salomon R.N., Underwood R., Doyle M.V., Wang A., Libby P. Increased apolipoprotein E and c-fms gene expression without elevated interleukin 1 or 6 mRNA levels indicates selective activation of macrophage functions in advanced human atheroma. Proc Natl Acad Sci USA 1992, 89:2814-2818.
61. Ehrenwald E., Chisolm G.M., Fox P.L. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 1994, 93:1493-1501.
62. Van Lenten B.J., Prieve J., Navab M., Hama S., Lusis A.J., Fogelman A.M. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995, 95:2104-2110.
63. Chisolm G.M., Hazen S.L., Fox P.L., Cathcart M.K. The oxidation of lipoproteins by monocytes-macrophages. J Biol Chem 1999, 274:25959-25962.
64. Camejo G., Halberg C., Manschik-Lundin A., et al. Hemin binding and oxidation of lipoproteins in serum: mechanisms and effect on the interaction of LDL with human macrophages. J Lipid Res 1998, 39:755-766.
65. Abdalla D.S., Campa A., Monteiro H.P. Low density lipoprotein oxidation by stimulated neutrophils and ferritin. Atherosclerosis 1992, 97:149-159.
66. Yoshida H., Sasaki K., Hirowatari Y., et al. Increased serum iron may contribute to enhanced oxidation of low-density lipoprotein in smokers in part through changes in lipoxygenase and catalase. Clin Chim Acta 2004, 345:161-170.
67. Lamb D.J., Leake D.S. Iron released from transferrin at acidic pH can catalyze the oxidation of low density lipoprotein. FEBS Lett 1994, 352:15-18.
68. Lamb D.J., Leake D.S. Acidic pH enables ceruloplasmin to catalyze the modification of low density lipoprotein. FEBS Lett 1994, 338:122-126.
69. Tribble D.L., Chu B.M., Levine G.A., Krauss R.M., Gong E.L. Selective resistance of LDL core lipids to iron-mediated oxidation. Implications for the biological properties of iron-oxidized LDL. Arterioscler Thromb Vasc Biol 1996, 16:1580-1587.
70. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992, 1128:117-131.
71. Sparrow C.P., Parthasarathy S., Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res 1988, 29:745-753.
72. Heydeck D., Upston J.M., Viita H., Ylä-Herttuala S., Stocker R. Oxidation of LDL by rabbit and human 15-lipoxygenase: prevalence of nonenzymatic reactions. J Lipid Res 2001, 42:1082-1088.
73. Xu W., Takahashi Y., Sakashita T., Iwasaki T., Hattori H., Yoshimoto T. Low density lipoprotein receptor-related protein is required for macrophage-mediated oxidation of low density lipoprotein by 12/15-lipoxygenase. J Biol Chem 2001, 276:36454-36459.
74. Zhu H., Takahashi Y., Xu W., et al. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem 2003, 278:13350-13355.
75. Takahashi Y., Zhu H., Xu W., et al. Selective uptake and efflux of cholesteryl linoleate in LDL by macrophages expressing 12/15-lipoxygenase. Biochem Biophys Res Commun 2005, 338:128-135.
76. Belkner J., Wiesner R., Rathman J., Barnett J., Sigal E., Kühn H. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur J Biochem 1993, 213:251-261.
77. Folcik V.A., Nivar-Aristy R.A., Krajewski L.P., Cathcart M.K. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 1995, 96:504-510.
78. Kühn H., Heydeck D., Hugou I., Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest 1997, 99:888-893.
79. Ylä-Herttuala S., Rosenfeld M.E., Parthasarathy S., et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 1990, 87:6959-6963.
80. Ylä-Herttuala S., Rosenfeld M.E., Parthasarathy S., et al. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest 1991, 87:1146-1152.
81. Shen J., Herderick E., Cornhill J.F., et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996, 98:2201-2208.
82. Merched A.J., Ko K., Gotlinger K.H., Serhan C.N., Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008, 22:3595-3606.
83. Huo Y., Zhao L., Hyman M.C., et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004, 110:2024-2031.
84. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999, 103:1597-1604.
85. Cyrus T., Praticò D., Zhao L., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001, 103:2277-2282.
86. George J., Afek A., Shaish A., et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 2001, 104:1646-1650.
87. Harats D., Shaish A., George J., et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2000, 20:2100-2105.
88. Kühn H., Römisch I., Belkner J. The role of lipoxygenase-isoforms in atherogenesis. Mol Nutr Food Res 2005, 49:1014-1029.
89. Klebanoff S.J. Myeloperoxidase: friend or foe. J Leukoc Biol 2005, 77:598-625.
90. Schindhelm R.K., van der Zwan L.P., Teerlink T., Scheffer P.G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clin Chem 2009, 55:1462-1470.
91. Heinecke J.W. Mass spectrometric quantification of amino acid oxidation products in proteins: insights in to pathways that promote LDL oxidation in the human artery wall. FASEB J 1999, 13:1113-1120.
92. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99:2075-2081.
93. Daugherty A., Dunn J.L., Rateri D.L., Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444.
94. Hazell L.J., Arnold L., Flowers D., Waeg G., Malle E., Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996, 97:1535-1544.
95. Brennan M.L., Anderson M.M., Shih D.M., et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001, 107:419-430.
96. Carr A.C., Myzak M.C., Stocker R., McCall M.R., Frei B. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett 2000, 487:176-180.
97. Day J.F., Thorpe S.R., Baynes J.W. Nonenzymatically glucosylated albumin. J Biol Chem 1979, 254:595-597.
98. Garlick R.L., Mazer J.S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem 1983, 258:6142-6146.
99. Kisugi R., Kouzuma T., Yamamoto T., et al. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 2007, 382:59-64.
100. Steinbrecher U.P., Witztum J.L. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes shows their catabolism. Diabetes 1984, 33:130-134.
101. Younis N., Sharma R., Soran H., Charlton-Menys V., Elseweidy M., Durrington P.N. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008, 19:378-384.
102. Schleicher E., Deufel T., Wieland O.H. Non-enzymatic glycosylation of human serum lipoproteins. Elevated epsilon-lysine glycosylated low density lipoprotein in diabetic patients. FEBS Lett 1981, 129:1-4.
103. Tames F.J., Mackness M.I., Arrol S., Laing I., Durrington P.N. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 1992, 93:237-244.
104. Sanguinetti S.M., Schreier L.E., Elbert A., Fasulo V., Ferrari N., Wikinski R.L. Detection of structural alterations in LDL isolated from type 2 diabetic patients: application of the fructosamine assay to evaluate the extent of LDL glycation. Atherosclerosis 1999, 143:213-215.
105. Kawamura M., Heinecke J.W., Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994, 94:771-778.
106. Yoshida H., Ishikawa T., Nakamura H. Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1997, 17:1438-1446.
107. Yoshida H., Ishikawa T., Ayaori M., et al. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 1998, 139:179-187.
108. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diab Care 2004, 27:1496-1504.
109. Koba S., Hirano T., Murayama S., et al. Small dense LDL phenotype is associated with postprandial increases of large VLDL and remnant-like particles in patients with acute myocardial infarction. Atherosclerosis 2003, 170:131-140.
110. Younis N., Charton-Menys V., Sharma R., Soran H., Durrington P.N. Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009, 202:162-168.
111. Menzel E.J., Sobal G., Staudinger A. The role of oxidative stress in the long-term glycation of LDL. Biofactors 1997, 6:111-124.
112. Li D., Devaraj S., Fuller C., Bucala R., Jialal I. Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies. J Lipid Res 1996, 37:1978-1986.
113. Imanaga Y., Sakata N., Takebayashi S., et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 2000, 150:343-355.
114. Bowie A., Owens D., Collins P., Johnson A., Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?. Atherosclerosis 1993, 102:63-67.
115. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993, 90:6434-6438.
116. Tsimikas S., Witztum J.L. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001, 103:1930-1932.
117. Hogg N., Kalyanaraman B., Joseph J., Struck A., Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993, 334:170-174.
118. Jessup W., Mohr D., Gieseg S.P., Dean R.T., Stocker R. The participation of nitric oxide in cell free- and its restriction of macrophage-mediated oxidation of low-density lipoprotein. Biochim Biophys Acta 1992, 1180:73-82.
119. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996, 271:C1424-C1437. Cell Physiol 40.
120. O'Donnell V.B., Chumley P.H., Hogg N., Bloodsworth A., Darley-Usmar V.M., Freeman B.A. Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with alpha-tocopherol. Biochemistry 1997, 36:15216-15223.
121. Berliner J.A., Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996, 20:707-727.
122. Malo-Ranta U., Ylä-Herttuala S., Metsä-Ketelä T., et al. Nitric oxide donor GEA 3162 inhibits endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett 1994, 337:179-183.
123. Hogg N., Struck A., Goss S.P., et al. Inhibition of macrophage-dependent low density lipoprotein oxidation by nitric-oxide donors. J Lipid Res 1995, 36:1756-1762.
124. Violi F., Marino R., Milite M.T., Loffredo L. Nitric oxide and its role in lipid peroxidation. Diabetes Metab Res Rev 1999, 15:283-288.
125. Denicola A., Batthyány C., Lissi E., Freeman B.A., Rubbo H., Radi R. Diffusion of nitric oxide into low density lipoprotein. J Biol Chem 2002, 277:932-936.
126. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991, 288:481-487.
127. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296:2391-2394.
128. Eiserich J.P., Hristova M., Cross C.E., et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998, 391:393-397.
129. Guthikonda S., Sinkey C., Barenz T., Haynes W.G. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003, 107:416-421.
130. Roob J.M., Rabold T., Hayn M., et al. Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD. Kidney Int Suppl 2001, 78:S128-S136.
131. Memon R.A., Staprans I., Noor M., et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000, 20:1536-1542.
132. Wang Z., Nicholls S.J., Rodriguez E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176-1184.